Neuronetics Grants 2025 Performance-Based Bonuses to Executives
TipRanks (Wed, 25-Feb 6:26 PM ET)
Diality Appoints Peter Donato as Chief Financial Officer
Business Wire (Tue, 24-Feb 7:05 AM ET)
Neuronetics' Clinic Revenue Jumps 37% and Positive Cash Flow Caps a Year of Rapid Expansion
Market Chameleon (Wed, 11-Feb 5:34 AM ET)
Globe Newswire (Tue, 10-Feb 4:34 PM ET)
STIM Sees Clinic Revenue Surge 25% and Achieves Cash Flow Milestones as CEO Plans Retirement
Market Chameleon (Tue, 4-Nov 5:41 AM ET)
Neuronetics Inc a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulations, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advanced Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address many of the key limitations of existing treatment options.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of February 27, 2026, STIM stock price declined to $1.34 with 915,748 million shares trading.
STIM has a beta of 1.46, meaning it tends to be more sensitive to market movements. STIM has a correlation of 0.07 to the broad based SPY ETF.
STIM has a market cap of $88.59 million. This is considered a Micro Cap stock.
Last quarter Neuronetics reported $37 million in Revenue and -$.13 earnings per share. This fell short of revenue expectation by $-666,600 and missed earnings estimates by -$.01.
In the last 3 years, STIM traded as high as $5.92 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): VTI, IWM, VXF, PSIL, IWO.
STIM has underperformed the market in the last year with a price return of -71.1% while the SPY ETF gained +16.6%. STIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -3.6% and -15.2%, respectively, while the SPY returned +1.2% and +0.7%, respectively.
STIM support price is $1.31 and resistance is $1.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.
